Compare Manchester United PLC (MANU) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs McKesson Corporation — how do they compare? Manchester United PLC trades at $20.51 (market cap $3.51B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 30.9× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and McKesson Corporation for 74 Days on average.
| MANU | MCK | |
|---|---|---|
Market Cap | $3.51B | $108.46B |
Volume | 412,769 | 712,607 |
Sector | Media | Health |
52-Week High | $24.19 | $995.69 |
52-Week Low | $15.20 | $725.17 |
Typical Hold Time | 109 Days | 74 Days |
Enterprise Value | $4.33B | $115.00B |
Dividend Yield | 1.26% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.51, up 1.28% with a bearish technical outlook. The company reported mixed Q4 2026 results, missing EPS estimates but beating revenue expectations. Despite posting a net loss of $33.02M in 2025, revenue grew to $666.51M. Analyst sentiment is divided with 40% buy ratings, while institutional ownership shows confidence with Gabelli Funds increasing its stake by 26.2% in Q1 2026.
MANU presents a speculative opportunity given its discounted valuation relative to franchise worth, but faces significant profitability challenges. The stock's upside depends on operational improvements and Champions League performance, while persistent losses and high debt levels remain key risks for investors.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
